Showing 8721-8730 of 19239 results for "".
- Streamlining Healthcare Technology and Patient Adherence: Addressing 504 Errors and Diabetic Retinopathy Screeninghttps://reachmd.com/news/streamlining-healthcare-technology-and-patient-adherence-addressing-504-errors-and-diabetic-retinopathy-screening/2471244/In the intersection of healthcare technology and patient care, understanding technical hurdles like 504 Gateway Time-out errors and improving patient adherence to screenings for conditions such as diabetic retinopathy can significantly influence outcomes.
- Renal Clues at Diagnosis: Uncovering Kidney Risk in New-Onset Diabeteshttps://reachmd.com/news/renal-health-and-guideline-compliance-in-newly-diagnosed-diabetes-mellitus/2474259/When patients are first diagnosed with diabetes mellitus, the clinical lens often zooms in on blood glucose control. But a growing body of evidence suggests another vital parameter deserves early attention: renal health. Research now points to a high prevalence of
- New UH Study Targets Early Signs of Vision Loss in Diabetic Patientshttps://reachmd.com/news/new-uh-study-targets-early-signs-of-vision-loss-in-diabetic-patients/2467853/A $3.3 million study at the University of Houston College of Optometry will track the health of patients with prediabetes and diabetes to find out who might develop eye problems and be at risk for future vision loss. The study is being led by Wendy Harrison, associate professor, and is under
- EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2https://reachmd.com/news/edta-chelation-no-help-in-cutting-cv-outcomes-after-mi-in-diabetic-patients-tact2/2462631/ATLANTA, GA—More than a decade after the TACT trial reported an astonishing reduction in cardiovascular events post-MI with heavy metal chelation in a subset of diabetic patients, the TACT2 trial, designed to test edetate disodium (EDTA) solely in a diabetic popu
- A New Biomarker Helps Detect Kidney Fibrosis in Transplant Patients Without Invasive Procedureshttps://reachmd.com/news/a-new-biomarker-helps-detect-kidney-fibrosis-in-transplant-patients-without-invasive-procedures/2468714/by Germans Trias i Pujol Research Institute
- AMT-191 Phase I/IIa Update: Durable α‑Gal A, Hepatic Signals, and Nephrology Implicationshttps://reachmd.com/news/amt-191-phase-iiia-update-durable-gal-a-hepatic-signals-and-nephrology-implications/2485605/Preliminary open-label data from the
- Exploring Social Determinants of Health and Treatment Disparities in Stage I Lung Cancer: Insights from Ontariohttps://reachmd.com/news/exploring-social-determinants-of-health-and-treatment-disparities-in-stage-i-lung-cancer-insights-from-ontario/2484983/An Ontario population-based cohort shows material deprivation is linked to lower receipt of surgical resection and greater reliance on radiotherapy or no treatment among adults with early-stage lung cancer, as reported in the
- Ethris Doses First Patient with Antiviral mRNA Drug in Phase I Asthma Trialhttps://reachmd.com/news/ethris-doses-first-patient-with-antiviral-mrna-drug-in-phase-i-asthma-trial/2463243/
- MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain with Oral Ketamir-2 in Breakthrough Studyhttps://reachmd.com/news/mira-pharmaceuticals-achieves-100-reversal-of-neuropathic-pain-with-oral-ketamir-2-in-breakthrough-study/2468049/Study Highlights Superior Efficacy of Ketamir-2 Over Oral Ketamine, Achieving Full Normalization of Pain ThresholdsMIAMI, FL / ACCESSWIRE / August 26, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a leading pre-clinical-stage pha
- Revolutionizing Pediatric Diabetes Care: The Role of Tirzepatidehttps://reachmd.com/news/revolutionizing-pediatric-diabetes-care-the-role-of-tirzepatide/2483463/As incretin-based therapies advance, clinicians are weighing early pediatric data on tirzepatide against established standards of care that prioritize metformin and insulin in youth, with limited use of GLP-1 receptor agonists. Within that context, tirzepatide—an emerging option in